Gene Editing
& Viral Vectors
Curing the blueprint of life: How we use molecular scissors and viral carriers to correct the root cause of LSDs.
01The Genetic Solution
Unlike ERT, which treats symptoms, gene therapy aims for a long-term fix. By delivering a corrected copy of the gene, the patient's own body starts producing the missing enzyme.
In-Vivo
A viral vector (the carrier) is injected directly into the patient to reach target organs or the brain.
Ex-Vivo
Cells are taken from the patient, edited in a high-tech lab, and transplanted back (often used for blood-based editing).
02The 2025 Innovation Roadmap
Modified AAV9 Serotypes
Engineering viral envelopes (capsids) that can cross the Blood-Brain Barrier with 10x higher efficiency, specifically targeting neural tissue.
Prime Editing (Search & Replace)
A precision editing method that can correct up to 89% of known genetic variants without causing double-strand breaks in DNA, significantly improving safety.
Self-Inactivating (SIN) Lentivirus
Vectors used in ex-vivo therapies (like for MLD) that naturally shut down after delivering the gene, preventing unintended genetic side effects.
AI-Driven CRISPR Design
Using large language models and structural biology AI to predict and prevent 'off-target' edits, ensuring the therapy only touches the intended gene.
Liver-Directed In-Vivo Platforms
Turning the liver into a permanent 'enzyme factory' by introducing healthy genetic sequences, eliminating the need for recurring treatments.
GT Innovation Watch
Searching for the latest Gene Therapy breakthroughs...
Ongoing Trials
Over 50 clinical trials for LSD Gene Therapy are now active globally. Stay informed.
Explore Trial Database